Enanta Pharmaceuticals reported that its oral RSV therapy, zelicapavir, narrowly missed the primary endpoint in a high-risk adult Phase 2b study but demonstrated positive signals in certain patient subgroups, signaling potential for further development. The company is planning to advance the treatment into larger trials to validate efficacy and safety, supported by investor confidence reflected in a near doubling of its stock following the data release. This progress underscores Enanta’s commitment to developing new antiviral therapeutics in a competitive landscape.